BeyondSpring (NASDAQ: BYSI) — Perfil da empresa, notícias e dados financeiros
BeyondSpring develops cancer therapies to improve outcomes, highlighted by its Plinabulin drug for chemotherapy-induced neutropenia.
BeyondSpring
BeyondSpring (NASDAQ:BYSI) is a global biopharmaceutical company focused on the development of innovative cancer therapies. It is known for its work on creating advanced treatments aiming to improve outcomes for patients facing serious oncological challenges. The company's flagship project involves the drug Plinabulin, which is designed to prevent chemotherapy-induced neutropenia (CIN) - a common and serious side effect of cancer treatment. BeyondSpring is committed to advancing its pipeline of novel medications through clinical trials with the goal of bringing new therapies to market. The company's efforts are driven by a dedication to enhancing the lives of those affected by cancer through the delivery of effective and safer treatment options.
Resumo
Operações
Produtos e/ou serviços de BeyondSpring
- Plinabulin, a novel cancer therapy with multiple indications including treatment for chemotherapy-induced neutropenia and non-small cell lung cancer.
- BPI-002, an oral small molecule for enhancing T cell activation to boost cancer immunotherapy effectiveness.
- BPI-003, a novel inhibitor targeting a key cancer cell growth and survival pathway.
- A pipeline of early-stage oncology assets exploring innovative approaches to cancer treatment.
- Collaborations on combination therapies to enhance the efficacy of current cancer treatment regimens.
- Research and development services related to oncology drug discovery for partner pharmaceutical and biotechnology companies.
equipe executiva do BeyondSpring
- Lan HuangCo-Founder & Chair of the Board
- June LuChief Scientific Officer
- Min QiuChief Executive Officer
- Li NaChief Financial Officer
- Stephen KilmerHead of Investor Relations
- John MaoSenior Vice President of Development
- Joy JiaVice President of Finance
Últimas notícias sobre a BeyondSpring
BeyondSpring receives FDA Fast Track designation for Plinabulin lung cancer program
United StatesBeyondSpring shares Phase 2 lung cancer data showing survival benefit
United StatesBeyondSpring reports Phase 3 survival success in NSCLC as SEED Therapeutics enters clinic
United StatesBeyondSpring unveils positive Asian subset results from Phase 3 DUBLIN-3 trial
United States
Principais indicadores financeiros
Resultados divulgados pela BeyondSpring, em USD.
- Cap. de mercado
- 21,6 mi
- Receita (TTM)
- 1,9 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.2
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -8,9 mi | -8 mi | |
| 0 | -8,8 mi | -11,1 mi | |
| 1,8 mi | -15,1 mi | -21 mi | |
| 1,4 mi | -37,2 mi | -33,3 mi |